Genzyme Ireland Limited (manufacturing of final product (fill/finish), batch control/testing, primary and secondary packaging, batch release authorization)

The drug is prescribed for long-term enzyme replacement therapy in adults and children aged 8 years and older with confirmed Fabry disease.

Dosage form: powder for preparation of concentrate for infusion solution

ATC: A16AB04